Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Open study with tiagabine in partial epilepsy].

S Arroyo1

  • 1Unidad de Epilepsia, Hospital Clínic de Barcelona, España.

Revista De Neurologia
|November 18, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Thoracic insufficiency syndrome].

Acta ortopedica mexicana·2021
Same author

Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study.

Acta neurologica Scandinavica·2010
Same author

Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk.

Human mutation·2008
Same author

[Interdigital erythrasma: clinical, epidemiologic, and microbiologic findings].

Actas dermo-sifiliograficas·2008
Same author

Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome.

Neurology·2008
Same author

[A pilot study on a specific measure for sleep disorders in Parkinson's disease: SCOPA-Sleep].

Revista de neurologia·2006
Same journal

The Correlation Between and Variability of Three Balance Scales in the Assessment of Balance Function in Patients With Ataxia.

Revista de neurologia·2026
Same journal

Surgical Treatment of an Aneurysm in the Subacute Stage of Hemorrhagic Moyamoya Disease: Aneurysm Resection Combined With STA-MCA Bypass: A Case Report.

Revista de neurologia·2026
Same journal

Mapping the Evidence: Central Sleep Apnea Syndromes During Sleep and Stroke-A Scoping Review.

Revista de neurologia·2026
Same journal

Developmental and Epileptic Encephalopathy Due to a Novel <i>ARHGEF9</i> Deletion Variant: Case Series of Two Siblings.

Revista de neurologia·2026
Same journal

P300 Event-Related Potentials as Cognitive Biomarkers in Neurological and Neuropsychiatric Disorders: A Systematic Review.

Revista de neurologia·2026
Same journal

[Effectiveness and Risk of Recurrence of Pulsed Radiofrequency in Trigeminal Neuralgia and Chronic Cluster Headache].

Revista de neurologia·2026
See all related articles

Tiagabine is an effective add-on therapy for partial epilepsy, significantly reducing seizure frequency in many patients. While side effects like somnolence occurred, they were generally mild and transient, indicating good tolerability.

Area of Science:

  • Clinical Neurology
  • Pharmacology
  • Epilepsy Research

Background:

  • Observational studies are crucial for assessing the real-world efficacy and safety of new anti-epileptic drugs (AEDs).
  • These studies provide insights into drug performance in typical clinical practice, complementing data from controlled trials.
  • Evaluating novel AEDs like tiagabine in diverse patient populations is essential for understanding their therapeutic potential.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of tiagabine as an add-on therapy in patients with partial epilepsy.
  • To assess seizure reduction rates and the incidence of side effects in a real-world clinical setting.
  • To determine the safety profile of tiagabine in patients with a history of multiple prior AED treatments.

Main Methods:

Related Experiment Videos

  • A multicenter observational trial conducted in Spain involving 645 patients with partial epilepsy.
  • Patients received tiagabine as add-on therapy, with dosages titrated up to a maximum of 70 mg/day.
  • Data collected included seizure characteristics, aetiology, and adverse events over a six-month follow-up period.

Main Results:

  • After six months, 29.4% of patients achieved complete seizure freedom, and 67% experienced over a 50% reduction in seizure frequency.
  • The average maintenance dose of tiagabine was 32.6 mg/day.
  • Adverse events, most commonly somnolence (28.2%), were reported in 52.4% of patients but were generally mild or transient; 25.7% discontinued treatment due to lack of efficacy or intolerance.

Conclusions:

  • Tiagabine demonstrates significant efficacy as an add-on treatment for partial epilepsy, leading to substantial seizure reduction in a majority of patients.
  • The drug is generally well-tolerated, with most side effects being mild and transient.
  • Tiagabine represents a valuable therapeutic option for patients with partial epilepsy, even those with a history of multiple treatment failures.